Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Main Article Content

Danny Rischin
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Nikhil Khushalani
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

Chryslalyne Schmults
Department of Dermatology, Brigham and Women?s Hospital, Harvard Medical School, Boston, MA

Alexander Guminski
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

Anne Lynn Chang
Department of Dermatology, Stanford University School of Medicine, Redwood City, CA

Karl Lewis
University of Colorado Denver, School of Medicine, Aurora, CO

Annette Lim
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Leonel Hernandez-Aya
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO

Brett Hughes
Royal Brisbane & Women?s Hospital and University of Queensland, Brisbane, Australia

Dirk Schadendorf
University Hospital Essen, Essen and German Cancer Consortium, Essen, Germany

Axel Hauschild
Schleswig-Holstein University Hospital, Kiel, Germany

Elizabeth Stankevich
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ

Jocelyn Booth
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ

Suk-Young Yoo
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ

Zhen Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Emmanuel Okoye
Regeneron Pharmaceuticals, Inc., London, UK

Israel Lowy
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Matthew Fury
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Micahel Migden
Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX

Keywords

Skin Cancer, Squamous Cell Carcinoma, Biologic, PD-1 Inhibitor, Cemiplimab

Abstract

Abstract not available.

References

1. Que SKT et al. J Am Acad Dermatol. 2018;78:237–247.

2. Cranmer LD et al. Oncologist. 2010;15:1320–1328.

3. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: squamous cell skin cancer (Version 2.2019). 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. [Accessed March 20, 2020].

4. Karia PS et al. J Clin Oncol. 2014;32:327–334.

5. Weinberg AS et al. Dermatol Surg. 2007;33:885–899.

6. Schmults CD et al. JAMA Dermatol. 2013;149:541–547.

7. Cowey C et al. Cancer Med. 2020 [in press].

8. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

9. Migden MR et al. Lancet Oncol. 2020;21:294–305.

10. Migden MR et al. N Engl J Med. 2018;379:341–351.

11. Rischin D et al. Poster presented at Maui Dermatology Conference, January 25–29, 2020.

12. Eisenhauer EA et al. Eur J Cancer. 2009;45:228–247.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.124

Article Details

How to Cite
[1]
Rischin, D., Khushalani, N., Schmults, C., Guminski, A., Chang, A.L., Lewis, K., Lim, A., Hernandez-Aya, L., Hughes, B., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Yoo, S.-Y., Chen, Z., Okoye, E., Lowy, I., Fury, M. and Migden, M. 2020. Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s124. DOI:https://doi.org/10.25251/skin.4.supp.124.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>